Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 6, 2013, Pages 898-903

  Bayraktar, Ulas D ^a   de Lima, Marcos ^a   Saliba, Rima M ^a   Maloy, Molly ^b   Castro Malaspina, Hugo R ^b   Chen, Julianne ^a   Rondon, Gabriela ^a   Chiattone, Alexander ^a   Jakubowski, Ann A ^b   Boulad, Farid ^b   Kernan, Nancy A ^b   O'Reilly, Richard J ^b   Champlin, Richard E ^a   Giralt, Sergio ^b   Andersson, Borje S ^a   Papadopoulos, Esperanza B ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AML; GVHD; Stem cell transplantation; T cell depletion; Transplant outcomes

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; LEUKOCYTE ANTIGEN; MELPHALAN; METHOTREXATE; PENTOSTATIN; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGRAFT; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; EX VIVO STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERFRACTIONATED TOTAL BODY IRRADIATION; IMMUNOMAGNETIC SEPARATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SOYBEAN LECTIN AGGLUTINATION; T CELL DEPLETED GRAFT; TREATMENT OUTCOME; UNMODIFIED ALLOGRAFT; WHOLE BODY RADIATION;

ADULT; AGED; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MALE; MELPHALAN; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; THIOTEPA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 84877899259     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.02.018     Document Type: Article

References (37)

1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
2. Kurosawa S., Yamaguchi T., Miyawaki S., et al. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood 2011, 117:2113-2120.
3. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
4. Champlin R.E., Passweg J.R., Zhang M.J., et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities. Blood 2000, 95:3996-4003.
5. Small T.N., Papadopoulos E.B., Boulad F., et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions. Blood 1999, 93:467-480.
6. Lee S.J., Zahrieh D., Alyea E.P., et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: Clinical outcomes, quality of life, and costs. Blood 2002, 100:2697-2702.
7. Wagner J.E., Thompson J.S., Carter S.L., Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): A multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
8. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23:3447-3454.
9. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
10. Jakubowski A.A., Small T.N., Young J.W., et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: Sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 2007, 110:4552-4559.
11. Papadopoulos E.B., Carabasi M.H., Castro-Malaspina H., et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease. Blood 1998, 91:1083-1090.
12. Boulad F, Jakubowski A, Papadopoulos EB, et al. Phase II trial of a chemotherapy-only regimen of busulfan, melphalan, fludarabine and R-ATG followed by allogeneic T-cell depleted hematopoietic stem cell transplants for the treatment of myeloid malignancies. 2007:2991a.
13. Devine S.M., Carter S., Soiffer R.J., et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: Results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 2011, 17:1343-1351.
14. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
15. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
16. Dreger P., Viehmann K., Steinmann J., et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Exp Hematol 1995, 23:147-154.
17. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
18. Andersson B.S., de Lima M., Thall P.F., et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
19. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
20. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
21. Martin P.J., Clift R.A., Fisher L.D., et al. HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: Analysis of survival and remission duration. Blood 1988, 72:1978-1984.
22. Drobyski W.R., Ash R.C., Casper J.T., et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994, 83:1980-1987.
23. Soiffer R.J., Fairclough D., Robertson M., et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 1997, 89:3039-3047.
24. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003, 102:1232-1240.
25. Jourdan E., Boiron J.M., Dastugue N., et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 2005, 23:7676-7684.
26. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom?. Blood 2007, 109:3658-3666.
27. Pasquini M.C., Devine S., Mendizabal A.M., et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012, 30:3194-3201.
28. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
29. Jakubowski A.A., Small T.N., Kernan N.A., et al. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant 2011, 17:1335-1342.
30. Keever-Taylor C.A., Bredeson C., Loberiza F.R., et al. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001, 7:620-630.
31. Kawanishi Y., Passweg J., Drobyski W.R., et al. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. Bone Marrow Transplant 1997, 19:1069-1077.
32. Wagner J.E., Santos G.W., Noga S.J., et al. Bone marrow graft engineering by counterflow centrifugal elutriation: Results of a phase I-II clinical trial. Blood 1990, 75:1370-1377.
33. Gupta V., Tallman M.S., He W., et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010, 116:1839-1848.
34. Keever C.A., Small T.N., Flomenberg N., et al. Immune reconstitution following bone marrow transplantation: Comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 1989, 73:1340-1350.
35. Soiffer R.J., Bosserman L., Murray C., et al. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood 1990, 75:2076-2084.
36. Heitger A., Winklehner P., Obexer P., et al. Defective T-helper cell function after T-cell-depleting therapy affecting naive and memory populations. Blood 2002, 99:4053-4062.
37. Fallen P.R., McGreavey L., Madrigal J.A., et al. Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant 2003, 32:1001-1014.